Exhibit 99.1
NAVIENT CORPORATION
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
On September 19, 2024, Navient Corporation (“Navient”) completed the sale of its equity interests in Xtend Healthcare, LLC, which comprised Navient’s Healthcare Services
business in Navient’s Business Processing segment, to Coding Solutions Acquisition, Inc. (“CorroHealth”) for $369 million ($365 million of total consideration, plus an estimated $4 million of working capital and other adjustments to the contractual
price) (the “Healthcare Services sale transaction”).
The following unaudited pro forma condensed consolidated balance sheet as of June 30, 2024, is presented as if the Healthcare Services sale transaction had occurred on
June 30, 2024.
The unaudited pro forma condensed consolidated statements of income for the year ended December 31, 2023, and the six months ended June 30, 2024, are presented as if the
Healthcare Services sale transaction had occurred on January 1, 2023. The estimated gain on sale in connection with the Healthcare Services sale transaction is reflected in the unaudited pro forma condensed consolidated balance sheet within equity.
The estimated gain on sale of $216 million is not reflected in the unaudited pro forma condensed consolidated statements of income as it does not have a continuing impact on Navient’s results.
The unaudited pro forma condensed consolidated financial information has been prepared from Navient's historical accounting records and, in accordance with Article 11 of
SEC Regulation S-X, is subject to the assumptions and adjustments described in the accompanying notes. These assumptions and adjustments are based on information presently available. Actual adjustments may differ materially from the information
presented. The unaudited pro forma condensed consolidated financial statements are based on the historical financial statements of Navient for each period presented and in the opinion of Navient management, all adjustments, and disclosures
necessary for a fair presentation of the pro forma data have been made.
The unaudited pro forma condensed consolidated financial information includes pro forma adjustments which reflect transactions and events that (a) are directly
attributable to the Healthcare Services sale transaction, (b) are factually supportable and (c) with respect to the statements of income, have a continuing impact on consolidated results. The pro forma adjustments are described in the accompanying
notes to the unaudited pro forma condensed consolidated financial statements. The unaudited pro forma condensed consolidated financial information does not reflect future events that may occur after the Healthcare Services sale transaction,
including any potential future cost savings that may be achieved.
These unaudited pro forma condensed consolidated financial statements are presented for illustrative purposes only and are not necessarily indicative of the results of
operations or financial condition that would have been achieved had events reflected been completed as of the dates indicated or of the results that may be obtained in the future. These unaudited pro forma condensed consolidated financial
statements and the notes thereto should be read together with Navient’s audited consolidated financial statements and the notes thereto as of and for the year ended December 31, 2023, and Management’s Discussion and Analysis included in Navient’s
Annual Report on Form 10-K for the year ended December 31, 2023, as well as Navient’s unaudited consolidated financial statements and the notes thereto as of and for the six months ended June 30, 2024, and Management’s Discussion and Analysis
included in Navient’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
As of June 30, 2024 (in millions)
|
|
As
|
|
|
Pro Forma
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
|
Pro Forma
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
FFELP Loans
|
|
$
|
32,940
|
|
|
$
|
-
|
|
|
|
$
|
32,940
|
|
Private Education Loans
|
|
|
16,238
|
|
|
|
-
|
|
|
|
|
16,238
|
|
Investments
|
|
|
132
|
|
|
|
-
|
|
|
|
|
132
|
|
Cash and cash equivalents
|
|
|
1,088
|
|
|
|
362
|
|
(A)
|
|
|
1,450
|
|
Restricted cash and cash equivalents
|
|
|
2,918
|
|
|
|
-
|
|
|
|
|
2,918
|
|
Goodwill and acquired intangible assets, net
|
|
|
690
|
|
|
|
(113
|
)
|
(B)
|
|
|
577
|
|
Other assets
|
|
|
2,616
|
|
|
|
(41
|
)
|
(B)
|
|
|
2,575
|
|
Total assets
|
|
$
|
56,622
|
|
|
$
|
208
|
|
|
|
$
|
56,830
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term borrowings
|
|
$
|
5,326
|
|
|
$
|
-
|
|
|
|
$
|
5,326
|
|
Long-term borrowings
|
|
|
47,545
|
|
|
|
-
|
|
|
|
|
47,545
|
|
Other liabilities
|
|
|
1,003
|
|
|
|
42
|
|
(B) (C)
|
|
|
1,045
|
|
Total liabilities
|
|
|
53,874
|
|
|
|
42
|
|
|
|
|
53,916
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
2,748
|
|
|
|
166
|
|
(D)
|
|
|
2,914
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
56,622
|
|
|
$
|
208
|
|
|
|
$
|
56,830
|
|
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the year ended December 31, 2023 (in millions, except per share amounts)
|
|
As
|
|
|
Pro Forma
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
|
Pro Forma
|
|
Total interest income
|
|
$
|
4,419
|
|
|
$
|
-
|
|
|
|
$
|
4,419
|
|
Total interest expense
|
|
|
3,557
|
|
|
|
-
|
|
|
|
|
3,557
|
|
Net interest income
|
|
|
862
|
|
|
|
-
|
|
|
|
|
862
|
|
Less: provisions for loan losses
|
|
|
123
|
|
|
|
-
|
|
|
|
|
123
|
|
Net interest income after provisions for loan losses
|
|
|
739
|
|
|
|
-
|
|
|
|
|
739
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Servicing revenue
|
|
|
64
|
|
|
|
-
|
|
|
|
|
64
|
|
Asset recovery and business processing revenue
|
|
|
321
|
|
|
|
(121
|
)
|
(E)
|
|
|
200
|
|
Other income
|
|
|
21
|
|
|
|
-
|
|
|
|
|
21
|
|
Losses on debt repurchases
|
|
|
(8
|
)
|
|
|
-
|
|
|
|
|
(8
|
)
|
Gains (losses) on derivative and hedging activities, net
|
|
|
11
|
|
|
|
-
|
|
|
|
|
11
|
|
Total other income
|
|
|
409
|
|
|
|
(121
|
)
|
|
|
|
288
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and benefits
|
|
|
401
|
|
|
|
(80
|
)
|
(E)
|
|
|
321
|
|
Other operating expenses
|
|
|
399
|
|
|
|
(21
|
)
|
(E)
|
|
|
378
|
|
Total operating expenses
|
|
|
800
|
|
|
|
(101
|
) |
|
|
|
699
|
|
Goodwill and acquired intangible asset impairment and amortization expense
|
|
|
10
|
|
|
|
(4
|
)
|
(E)
|
|
|
6
|
|
Restructuring/other reorganization expenses
|
|
|
25
|
|
|
|
(2
|
)
|
(E)
|
|
|
23
|
|
Total expenses
|
|
|
835
|
|
|
|
(107
|
)
|
|
|
|
728
|
|
Income before income tax expense
|
|
|
313
|
|
|
|
(14
|
)
|
|
|
|
299
|
|
Income tax expense
|
|
|
85
|
|
|
|
(3
|
)
|
(F)
|
|
|
82
|
|
Net income
|
|
$
|
228
|
|
|
$
|
(11
|
)
|
|
|
$
|
217
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share Amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per common share
|
|
$
|
1.87
|
|
|
|
|
|
|
|
$
|
1.78
|
|
Average common shares outstanding
|
|
|
122
|
|
|
|
|
|
|
|
|
122
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per common share
|
|
$
|
1.85
|
|
|
|
|
|
|
|
$
|
1.76
|
|
Average common and common equivalent shares outstanding
|
|
|
123
|
|
|
|
|
|
|
|
|
123
|
|
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the six months ended June 30, 2024 (in millions, except per share amounts)
|
|
As
|
|
|
Pro Forma
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
|
Pro Forma
|
|
Total interest income
|
|
$
|
2,000
|
|
|
$
|
-
|
|
|
|
$
|
2,000
|
|
Total interest expense
|
|
|
1,718
|
|
|
|
-
|
|
|
|
|
1,718
|
|
Net interest income
|
|
|
282
|
|
|
|
-
|
|
|
|
|
282
|
|
Less: provisions for loan losses
|
|
|
26
|
|
|
|
-
|
|
|
|
|
26
|
|
Net interest income after provisions for loan losses
|
|
|
256
|
|
|
|
-
|
|
|
|
|
256
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Servicing revenue
|
|
|
35
|
|
|
|
-
|
|
|
|
|
35
|
|
Asset recovery and business processing revenue
|
|
|
158
|
|
|
|
(60
|
)
|
(E)
|
|
|
98
|
|
Other income
|
|
|
13
|
|
|
|
-
|
|
|
|
|
13
|
|
Gains (losses) on derivative and hedging activities, net
|
|
|
46
|
|
|
|
-
|
|
|
|
|
46
|
|
Total other income
|
|
|
252
|
|
|
|
(60
|
)
|
|
|
|
192
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and benefits
|
|
|
188
|
|
|
|
(38
|
)
|
(E)
|
|
|
150
|
|
Other operating expenses
|
|
|
162
|
|
|
|
(9
|
)
|
(E)
|
|
|
153
|
|
Total operating expenses
|
|
|
350
|
|
|
|
(47
|
) |
|
|
|
303
|
|
Goodwill and acquired intangible asset impairment and amortization expense
|
|
|
5
|
|
|
|
(2
|
)
|
(E)
|
|
|
3
|
|
Restructuring/other reorganization expenses
|
|
|
17
|
|
|
|
-
|
|
(E)
|
|
|
17
|
|
Total expenses
|
|
|
372
|
|
|
|
(49
|
)
|
|
|
|
323
|
|
Income before income tax expense
|
|
|
136
|
|
|
|
(11
|
)
|
|
|
|
125
|
|
Income tax expense
|
|
|
27
|
|
|
|
(3
|
)
|
(F)
|
|
|
24
|
|
Net income
|
|
$
|
109
|
|
|
$
|
(8
|
)
|
|
|
$
|
101
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per Share Amounts:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
$
|
0.98
|
|
|
|
|
|
|
|
$
|
0.90
|
|
Average common shares outstanding
|
|
|
112
|
|
|
|
|
|
|
|
|
112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share
|
|
$
|
0.97
|
|
|
|
|
|
|
|
$
|
0.89
|
|
Average common and common equivalent shares outstanding
|
|
|
113
|
|
|
|
|
|
|
|
|
113
|
|
NOTES TO THE UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(A) Adjustment represents the net cash received from the sale of our Healthcare Services business ($369 million of cash consideration less $7 million
of estimated cash costs directly associated with the transaction).
(B) Adjustments represent the elimination of the assets and liabilities of our Healthcare Services business that was sold.
(C) Adjustment represents an increase in current tax liabilities of $50 million as a result of the gain recognized on the sale of our Healthcare
Services business offset by the elimination of $8 million of liabilities attributable to our Healthcare Services business.
(D) Adjustments reflect the pretax gain on the sale of our HealthCare Services business of $216 million ($166 million net of tax) calculated as
follows:
(in millions)
|
|
|
|
Cash received (net of selling and other expenses)
|
|
$
|
362
|
|
Less: Carrying value in Healthcare Services business
|
|
|
146
|
|
Pro forma gain before income tax expense
|
|
|
216
|
|
Less: Income tax expense
|
|
|
50
|
|
Pro forma net gain on sale of our Healthcare Services business
|
|
$
|
166
|
|
The pro forma net gain of $166 million is reflected as an adjustment to retained earnings. This amount is based on historical information as of June 30, 2024 for Navient Corporation's carrying value of its Healthcare Services business. The
actual net gain will be based on Navient Corporation's carrying value in the Healthcare Services business as of September 19, 2024.
(E) Adjustments reflect the elimination of revenues, costs and expenses directly attributable to our Healthcare Services business. Adjustments do not
include: (1) certain general corporate and segment overhead costs previously allocated to the Healthcare Services business that will have a continuing effect on Navient post-closing or (2) any potential future cost savings that may be achieved.
(F) Adjustment reflects the estimated income tax effect of the pro forma adjustments at the statutory rate directly related to the Healthcare Services
business.
5